Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown
9 years ago
R&D
Bind burial complete, Andrew Hirsch lands the CFO’s job at high-profile Agios
9 years ago
People
Pharma
Hopes fading, OncoGenex acknowledges a PhIII flop for cancer drug
9 years ago
R&D
Sorrento's new pain player Scintilla going solo after $200M buyout deal
9 years ago
R&D
Vertex shutters a PhIII cystic fibrosis combo study, shares slip
9 years ago
R&D
Will some pent-up deal pressure amp up a biotech rally?
9 years ago
R&D
Protocols: Bavarian collaborates with BMS on lung cancer study; Eleven completes Roche deal; Intellia chief ...
9 years ago
R&D
Facing questions on patient deaths, Aurinia shares crater in wake of lupus study
9 years ago
R&D
FDA to Chiasma on their Phase III rejection: Come up with a better plan next time
9 years ago
R&D
Working to get its pain R&D strategy back on track, AcelRx steps closer to an FDA pitch
9 years ago
R&D
Zymeworks bags a protein engineering platform as it preps for an IPO
9 years ago
R&D
AstraZeneca gets a boost from durvalumab PhIII chatter as pipeline wear and tear starts to show
9 years ago
R&D
Thumbs Up/Thumbs Down: The FDA backs another R&D scheme, Kite shows its speed while Eli Lilly and Astra stumble again
9 years ago
Bioregnum
Opinion
Biotech venture champion Bill Maris is exiting GV. What’s next?
9 years ago
R&D
Protocols: Infinity hunts up a buyer for its disappointing cancer drug duvelisib; Is Northwest Bio finally broke?
9 years ago
News Briefing
Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead
9 years ago
R&D
Protagonist’s IPO option delivers a $90M payoff for early-stage peptide work
9 years ago
R&D
The Brent Saunders way: Allergan pays $95M for its next stepping stone to a bigger pipeline
9 years ago
R&D
Another old drug looks for a second coming at the FDA, this time for Duchenne MD
9 years ago
R&D
Microbiome upstart Vedanta teams up with NYU Langone scientist on checkpoint drugs
9 years ago
R&D
An introduction to the Endpoints 100
9 years ago
Bioregnum
Opinion
AstraZeneca doubles down on Moderna, invests $140M in $1.5B-plus biotech
9 years ago
R&D
Heron shares fly up after FDA (finally) approves its drug to rein in chemo side effects
9 years ago
R&D
Frustrated Eli Lilly may have to settle for a lonely last-place finish in the blockbuster CDK 4/6 race
9 years ago
R&D
First page
Previous page
1168
1169
1170
1171
1172
1173
1174
Next page
Last page